More than one in 10 COVID-19 patients in 314 UK hospitals caught the infection in hospital during the first wave of the pandemic, finds a new study carried out in collaboration with the University of Birmingham.
A new study exposes the dire need for new clinical risk management tools to help hospital healthcare workers prevent the deaths and intensive care admissions of BAME COVID-19 patients with pneumoni.
Dr Amy Naylor is a Senior Research Fellow and member of the Rheumatology Research Group within the Institute of Inflammation and Ageing.
Patients isolating before surgery - mainly to avoid COVID-19 and its complications – are at a 20% increased risk of developing post-operative lung complications compared with patients who do not isolate.
Patients isolating before surgery to avoid COVID-19 complications have a 20% increased risk of post-operative lung issues compared to non-isolating patients.
A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70%.
The most comprehensive study so far of genetic diversity in the Middle East has given a glimpse into the lives of ancient humans who lived through seismic events including the formation of the Arabian Desert.
The University of Birmingham will co-ordinate a major UK trial to analyse the efficacy of cannabis-based drug Sativex in treating the most aggressive form of brain tumours.
Dr Neena Kalia, Reader at the Institute of Cardiovascular Sciences, has been awarded a three-year BHF research grant to find out what damage diabetes does to the smallest blood vessels of the heart.
A new £850k collaboration between Birmingham Health Partners and global biotechnology leaders Roche is set to improve both diagnosis and care of patients with inflammatory bowel disease.
A major study led by the University of Birmingham has revealed that a lack of available specialist consultants in hospitals at the weekend is not the cause of the so-called 'weekend effect'.
Birmingham researchers partnered with Cancer Research UK in one of the first target identification projects for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer patients.